Article: The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens—R. Mann et. al.
Source: Aliment Pharmacol Ther. 2017;46:46–55
Study Aims and Results:The objective of the study was to assess the risk of acute (rapid onset) of kidney disease with sofosbuvir-based treatments or telaprevir/boceprevir-based therapies at tertiary (specialty care) university centers. This was a retrospective study (looking back at previous studies) in people without pre-existing kidney disease.
A total of 426 patients were included in the study—233 (55%) patients treated with sofosbuvir-based therapies and 193 (45%) patients with telaprevir/boceprevir-based therapies (telaprevir/boceprevir were older types of direct-acting antiviral HCV therapies that are no longer used).
In the group that received telaprevir/boceprevir-based therapies 34 (18%) experienced acute kidney disease compared to 26 (11%) who experienced acute kidney disease in the sofosbuvir-based therapies. Analyzing the data, the authors concluded that ascites (accumulation of fluid in the stomach or abdominal area) and non-steroidal anti-inflammatory(NSAIDs) use were contributing factors to acute kidney disease in sofosbuvir-based therapies.
In the patients who took the sofosbuvir-based therapy group, 23 of the 26 patients who initially had acute kidney disease, kidney function returned to normal–this was the number of people who were available during the follow-up period.
Conclusion: Sofosbuvir-based therapies to treat hepatitis C in people without pre-existing kidney disease can produce acute kidney disease in a minority of people. However, in the available follow-up data, kidney function returned to normal.
Editorial Comments: For people with acute kidney disease while on sofosbuvir-based therapies, the absence of long-term danger is reassuring. Of course, any acute disease should be followed carefully. It is also reassuring that we have moved on from telaprevir and boceprevir!
Did you know that NSAIDs account for 100,000 hospitalizations and 16,000 deaths each year in the United States.*